|
ToxiPharm LLC
ToxSignal
Clinical Toxicology Intelligence
|
Issue
#07
June 2026
|
|
|
|
Hi *|FNAME|*,
A 22-year-old shows up in opioid withdrawal with no history of opioid use at all. His only exposure was a vape cartridge sold online as a cannabinoid product. That case anchors this issue, and it is a sign that nitazenes have moved from an overdose problem to a withdrawal problem clinicians do not yet have real dosing guidance for. This month's Tox Pearl (#7) goes deeper on the clinical picture if you want it.
On the policy side, HHS quietly opened a real funding lane for MOUD through Title IV-E, worth a look if you touch family drug courts or child-welfare-adjacent treatment. And buried in a 600,000-veteran study: GLP-1 medications may be doing something nobody expected across nearly every substance, not just diabetes and weight loss.
|
|
|
◆ Drug Trend Spotlight
|
Nitazene Withdrawal Is a New Clinical Entity. Standard Buprenorphine Doses May Not Be Enough.
Nitazenes are benzimidazole synthetic opioids whose potency can exceed fentanyl, and a New South Wales surveillance program has now documented something new: regular nitazene use can produce a genuine physical dependence with its own withdrawal syndrome. Of 27 laboratory-confirmed nitazene opioid exposures identified over nearly seven years (June 2018 to March 2025), 20 were unintentional acute poisonings and 7 presented in acute withdrawal, a pattern the authors specifically flagged as a novel clinical observation. Vaping was the most common route of exposure, and protonitazene, protonitazepyne, and isotonitazene were the most frequently detected compounds.
A companion case report puts a clinical face on that finding: a previously opioid naive 22-year-old developed dependence from vaping a product sold online as a cannabinoid, then required buprenorphine doses higher than standard induction protocols call for, plus adjunctive diazepam and olanzapine, before his withdrawal was controlled. There are currently no published studies establishing what buprenorphine dose actually works for nitazene-dependent patients, so clinicians are extrapolating from protocols built for a lower-potency opioid landscape.
|
Why it matters
If a patient reports vaping or using a product they did not know contained nitazenes and presents in withdrawal that is not responding to a standard buprenorphine dose, escalate dosing and add adjunctive medication early rather than waiting for a slow taper to catch up. This month's Tox Pearl (#7) covers the full clinical picture: download it free at toxipharm.org/education.html.
|
Roberts DM, Tisdell B, Sajeev MF, Jiranantakan T, Harvey C, Brown JA. Clinical experiences with the nitazene class of synthetic opioids: a cohort study. Ann Emerg Med. 2025;86(5):475-483. PMID 40810707 · Dutkiewicz D, Wilson H, Jiranantakan T, et al. Management of opioid withdrawal syndrome and commencement of opioid dependence treatment following chronic use of a vaping product containing protonitazene: case report. Drug Alcohol Rev. 2026;45(1):e70104. PMID 41578432
|
|
|
|
|
◆ Regulatory & Policy Update
| |
Status: Final Policy; Announced June 2026
HHS Adds Buprenorphine, Methadone, and Naltrexone as Title IV-E Prevention Services. Here Is What That Unlocks.
The Administration for Children and Families (ACF) announced that all three FDA-approved medications for opioid use disorder, buprenorphine, methadone, and naltrexone, are now eligible for funding under Title IV-E as prevention services. States and tribes can draw a 50% federal match to fund MOUD for parents when children are at imminent risk of entering foster care.
This lands alongside a separate, state-level development: the Virginia Opioid Abatement Authority approved more than $35.2 million in June 2026 for 150 projects spanning prevention, treatment, recovery support, harm reduction, and workforce development across the Commonwealth. For family drug courts and child-welfare-adjacent treatment programs, particularly here in Virginia, the practical opportunity is stacking: a Title IV-E match alongside abatement-funded wraparound services can cover more of a parent's treatment episode than either funding stream alone.
If you operate or advise a family drug court, CTC, or child-welfare-adjacent treatment program, this is worth a direct look at how your state plans to draw down the new match and whether it can be layered with abatement or other existing funding.
Administration for Children and Families. HHS Expands Access to Medications for Opioid Use Disorder for At-Risk Families. Press release. 2026. · ACF press release → · Virginia Opioid Abatement Authority. Award announcements. June 2026. OAA releases →
|
|
|
|
|
◆ Science Worth Reading
|
COHORT STUDY / 600,000+ VETERANS
GLP-1 Medications Are Tied to a 14% Lower Risk of Developing Any Substance Use Disorder.
A WashU Medicine cohort study of 606,434 U.S. veterans with type 2 diabetes, published March 4, 2026 in The BMJ, found that GLP-1 receptor agonist use (most commonly semaglutide, liraglutide, or dulaglutide) was associated with a 14% reduced risk of developing any substance use disorder compared to a non-GLP-1 diabetes medication, with risk reductions ranging from 18% for alcohol to 25% for opioids and nicotine. Among veterans who already had a substance use disorder, GLP-1 use was tied to a 30% reduction in drug-related emergency department visits, a 25% reduction in hospitalizations, a 40% reduction in overdose, and a 50% reduction in drug-related death over three years.
|
My Take
This is observational data, not a randomized trial, and no GLP-1 medication is FDA-approved for substance use disorder; do not read this as a green light to prescribe off-label for that indication alone. What makes it worth tracking is the cross-substance signal: the same drug class showed a benefit across alcohol, cannabis, cocaine, nicotine, and opioids, which points to a shared craving pathway rather than a drug-specific effect. If a patient is already on a GLP-1 for diabetes or weight management and also has a co-occurring substance use disorder, this is a reasonable data point to discuss, not a treatment plan to build around yet. Trials designed specifically to test GLP-1s for addiction, including endpoints powered for overdose and death, are the next thing to watch for.
|
Cai M, Choi T, Xie Y, Al-Aly Z. GLP-1RA and risks of substance use disorders among US veterans with type 2 diabetes: a cohort study. BMJ. 2026;392:bmj-2025-086886. · Full text →
|
|
|
|
From Bill
"This issue captures something I keep coming back to in this field: we are simultaneously behind and ahead. The nitazene case report describes a clinical problem we do not have a real answer for yet, what dose of buprenorphine actually treats withdrawal from a compound that can be more potent than fentanyl. Nobody has published that number. At the same time, the GLP-1 data below suggests a completely unrelated drug class might end up working against addiction broadly, across nearly every substance, through a shared craving pathway nobody fully appreciated a few years ago. Staying current in this field means watching the new threats and the new tools at the same time, because this week they showed up in the same inbox."
Dr. William Bundy Jr., PharmD
Clinical Toxicologist & Consultant · ToxiPharm LLC
|
|
ToxiPharm LLC
Clinical toxicology consulting, expert review, UDT interpretation, and Tox In Focus clinical references.
toxipharm.org
|
|
Clinical Disclaimer
Content in this newsletter is intended for clinical reference and educational purposes for use by qualified clinicians, medical review officers, and drug program administrators. It does not represent an all-inclusive review of available evidence. Clinical data, regulatory guidance, and laboratory standards evolve; readers should verify current requirements with applicable authorities. Content in this newsletter does not constitute medical, legal, or regulatory advice and should not replace independent clinical judgment. ToxiPharm LLC makes no warranties regarding completeness or applicability in all clinical situations. © 2026 ToxiPharm LLC · toxipharm.org
|
|
ToxiPharm LLC · Clinical Toxicology & Regulatory Consulting
*|HTML:LIST_ADDRESSLINE|*
You're receiving ToxSignal because you subscribed at toxipharm.org.
Manage preferences
·
Unsubscribe
|
|